medigraphic.com

2013, Número 1

<< Anterior Siguiente >>

Rev Hosp Jua Mex 2013; 80 (1)


Farmacocinética: antiulcerosos y antiinflamatorios

Martínez-Hernández E, Garrido-Acosta O

Idioma: Español
Referencias bibliográficas: 28
Paginas: 41-53
Archivo PDF: 161.80 Kb.


RESUMEN

Se revisan los aspectos de absorción, distribución, metabolismo y excreción de los fármacos antiulcerosos y antiinflamatorios con mayor frecuencia utilizados en la práctica clínica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Oates JA, Roden DM, Wilkinson GR. Principles of drug therapy. En: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson LJ. Harrison’s Principles of Internal Medicine. 15th Ed. New York: McGraw-Hill; 2001, p. 419-30.

  2. Drug interactions. Med Letter 1999; 41: 61-2.

  3. Soll AH. Peptic ulcer and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, Sleisenger, Fordtran’s. Gastrointestinal and Liver Disease. Vol. 1. 6th Ed. Philadelphia. WB Saunders; 1998, p. 620-78.

  4. Drugs for treatment of peptic ulcer. Med Letter 1997; 39: 1-4.

  5. Vivian EM, Thomson Maya A. Pharmacologic Strategies for treating Gastroesophageal Reflux Disease. Clin Therapeutics 2000; 22: 654-72.

  6. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: role of drug interactions. Clin Pharmacokinet 2000; 39: 295-309.

  7. Arora AS, Castell DO. Medical Therapy for Gastroesophageal Reflux Disease. Mayo Clin Proc 2001; 76: 102-6.

  8. Welage LS, Berardi RR. Drug interactions with antiulcer agents: Considerations in the treatment of acid-peptidic disease. J Pharm Pract 1994; 7: 177-95.

  9. Powell JR. Inhibition of teophylline clearance by cimetidine. Arch Intern Med 1997; 144: 484-6.

  10. Horn J. The proton-pump inhibitors: similarities and differences. Clin Therapeutics 2000; 22: 266-80.

  11. Adersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole, and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.

  12. Andersson T, Miners JO, Veronese ME. Identification of human liver chromosome P-450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-30.

  13. Maton PN, Burton ME. Antacids revisited. A review of their clinical pharmacology and recommended therapeutic use. Drugs 1999; 57: 855-70.

  14. D’Arcy PF, Mc Elnay JC. Drug-antacid interactions: assessment of clinical importance. Drug Intell Clin Pharm 1987; 21: 607-17.

  15. Neuvonen PJ, Tokola RA, Kaste M. Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol 1981; 21: 215-20.

  16. Greenblat DJ, Abernethy DR, Morse DS. Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med 1984; 310: 1639-43.

  17. Piquette RK. Torsade de pointes induced by cisapride/ clarithromicin interaction. Ann Pharmacoter 1999; 33: 22-6.

  18. Maton PN. Omeprazole. N Eng J Med 1991; 324: 965-75.

  19. Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001; 16: 723-8.

  20. Cavuto NJ, Flockhart DA. Effect of omeprazole on teophylline clerance in poor metabolizers of omeprazole. Clin Pharmacol Ther 1995; 57: 215.

  21. Barradell LD, Fauda D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44: 225-50.

  22. Rabeprazole. Med Letter 1999; 41: 110-2.

  23. Caos A, Moskovitz M, Dayal Y, Perdomo C, Niecestro R, Barth J. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 3081-8.

  24. Lanza F, Bardhan KD, Perdomo C, Niecestro R, Barth J. Efficacy of rabeprazole once-daily for acid related disorders. Dig Dis Sci 2001; 46: 587-96.

  25. Humphries TA. A review of the drug-drug interaction potential of rabeprazole sodium based on CYP-450 interference or absorption effects. Digestion 1998; 59 (Suppl.): 76.

  26. Pantoprazole. Med Letter 2000; 42: 65-6.

  27. Avner DL. Clinical experience with pantoprazole in gastroesophageal reflux disease. Clin Ther 2000; 22: 1169-85.

  28. Middle MV, Muller FO, Schall R. No influence of pantoprazole on the pharmacokinetics of phenytoin. Int J Clin Pharmacol Ther 1996; 34: S72-S75.




2020     |     www.medigraphic.com